This article is part of the Topical Collection on High-risk Obstetrics
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The US opioid epidemic continues historic trends of disproportionately affecting women. However, attention to the rise in neonatal opioid withdrawal syndrome (NOWS) and other types of neonatal care often overshadow the urgent need for improved and more wide-ranging maternal treatment in the peripartum period.
This review aims to highlight the trends in maternal morbidity and mortality related to substance use disorder (SUD), to discuss the under-funding of woman-focused interventions, and to discuss medication-assisted treatment (MAT) options for women with SUD. We found that the rates of pregnancy-related mortality are highest for SUD-related deaths and remains at crisis levels.
Women continue to face barriers to treatment access, and there is a critical need to provide new mothers in recovery with more comprehensive and supportive care in the peripartum period.
CDC WONDER. https://wonder.cdc.gov/. Accessed 3 Oct 2018.
Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901–6. CrossRef
Opioid overdose deaths increasing. https://www.healthline.com/health-news/deaths-from-opioid-overdoses-higher-than-car-accident-fatalities#1. Accessed 3 Oct 2018.
Opioids – Cook County Health and Hospitals System. http://www.cookcountyhhs.org/opioids/. Accessed 3 Oct 2018.
Why Connecticut’s drug overdose crisis isn’t slowing down | The Opioid Epidemic. https://overdose.trendct.org/. Accessed 3 Oct 2018.
Bleak new estimates in drug epidemic: a record 72,000 overdose deaths in 2017 - The New York Times. https://www.nytimes.com/2018/08/15/upshot/opioids-overdose-deaths-rising-fentanyl.html. Accessed 3 Oct 2018.
Terplan M. Women and the opioid crisis: historical context and public health solutions. Fertil Steril. 2017;108:195–9. CrossRef
PhD HEJ. Treating opioid use disorders during pregnancy: historical, current, and future directions. Subst Abuse. 2013;34:89–91. CrossRef
Trickey E. Inside the story of America’s 19th-century opiate addiction. Smithsonian. https://www.smithsonianmag.com/history/inside-story-americas-19th-century-opiate-addiction-180967673/. Accessed 3 Oct 2018.
McHugh RK, DeVito EE, Dodd D, Carroll KM, Potter JS, Greenfield SF, et al. Gender differences in a clinical trial for prescription opioid dependence. J Subst Abus Treat. 2013;45:38–43. CrossRef
Parsells Kelly J, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138:507–13. CrossRef
Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstet Gynecol. 2014;123:997–1002. CrossRef
Krans EE, Patrick SW. Opioid use disorder in pregnancy: health policy and practice in the midst of an epidemic. Obstet Gynecol. 2016;128:4–10. CrossRef
Vital Signs: Overdoses of prescription opioid pain relievers and other drugs among women — United States, 1999–2010. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6226a3.htm. Accessed 27 Dec 2016.
Terplan M, Hand DJ, Hutchinson M, Salisbury-Afshar E, Heil SH. Contraceptive use and method choice among women with opioid and other substance use disorders: a systematic review. Prev Med. 2015;80:23–31. CrossRef
Heil SH, Jones HE, Arria A, Kaltenbach K, Coyle M, Fischer G, et al. Unintended pregnancy in opioid-abusing women. J Subst Abus Treat. 2011;40:199–202. CrossRef
Black KI, Stephens C, Haber PS, Lintzeris N. Unplanned pregnancy and contraceptive use in women attending drug treatment services. Aust N Z J Obstet Gynaecol. 2012;52:146–50. CrossRef
ACOG Statement on opioid use during pregnancy - ACOG. http://www.acog.org/About-ACOG/News-Room/Statements/2016/ACOG-Statement-on-Opioid-Use-During-Pregnancy. Accessed 21 Nov 2016.
WHO | Guidelines for identification and management of substance use and substance use disorders in pregnancy. WHO. http://www.who.int/substance_abuse/publications/pregnancy_guidelines/en/. Accessed 19 Dec 2016.
Tolia VN, Patrick SW, Bennett MM, Murthy K, Sousa J, Smith PB, et al. Increasing incidence of the neonatal opioid withdrawal syndrome in U.S. neonatal ICUs. N Engl J Med. 2015;372:2118–26. CrossRef
Raffaeli G, Cavallaro G, Allegaert K, Wildschut ED, Fumagalli M, Agosti M, et al. Neonatal opioid withdrawal syndrome: update on diagnostic and therapeutic strategies. Pharmacother J Hum Pharmacol Drug Ther. 2017;37:814–23. CrossRef
Short VL, Gannon M, Abatemarco DJ. The association between breastfeeding and length of hospital stay among infants diagnosed with neonatal opioid withdrawal syndrome: a population-based study of in-hospital births. Breastfeed Med. 2016;11:343–9. CrossRef
McCarthy JJ, Leamon MH, Finnegan LP, Fassbender C. Opioid dependence and pregnancy: minimizing stress on the fetal brain. Am J Obstet Gynecol. 2016;215:670.e1–2. CrossRef
Nih Reporter Query Form - Fill Online, Printable, Fillable, Blank | PDFfiller. https://www.pdffiller.com/6651396-fillable-nih-reporter-query-form-fnih. Accessed 20 Nov 2018.
MacDorman MF, Declercq E, Cabral H, Morton C. Is the United States maternal mortality rate increasing? Disentangling trends from measurement issues Short title: U.S. maternal mortality trends. Obstet Gynecol. 2016;128:447–55. CrossRef
Hirshberg A, Srinivas SK. Epidemiology of maternal morbidity and mortality. Semin Perinatol. 2017;41:332–7. CrossRef
• Kilpatrick SJ. Trauma in pregnancy: an underappreciated cause of maternal death. Am J Obstet Gynecol. 2017;217:499–500 A great editorial highlighting how commonly used statistical terms characterizing maternal death often under-captures the true rates of mortality from overdose. CrossRef
Krulewitch CJ, Pierre-louis ML, De Leon-Gomez R, Guy R, Green R. Hidden from view: violent deaths among pregnant women in the District of Columbia, 1988-1996. J Midwifery Womens Health. 2001;46(1):4–10. CrossRef
Chang J, Berg CJ, Saltzman LE, Herndon J. Homicide: a leading cause of injury deaths among pregnant and postpartum women in the United States, 1991-1999. Am J Public Health. 2005;95(3):471–7. CrossRef
Hardt N, Wong TD, Burt MJ, Harrison R, Winter W, Roth J. Prevalence of prescription and illicit drugs in pregnancy-associated non-natural deaths of Florida mothers, 1999-2005. J Forensic Sci. 2013;58(6):1536–41. CrossRef
Mehta PK, Bachhuber MA, Hoffman R, Srinivas SK. Deaths from unintentional injury, homicide, and suicide during or within 1 year of pregnancy in Philadelphia. Am J Public Health. 2016;106:2208–10. CrossRef
• Metz TD, Rovner P, Hoffman MC, Allshouse AA, Beckwith KM, Binswanger IA. Maternal deaths from suicide and overdose in Colorado, 2004–2012. Obstet Gynecol. 2016. A very good study identifying self-harm and overdose as major causes of pregnancy-associated deaths in the context of social supports and mental health disorders.
Maternal Mortality and Morbidity Initiative | Mass.gov. https://www.mass.gov/service-details/maternal-mortality-and-morbidity-initiative. Accessed 10 Oct 2018.
•• Schiff DM, Nielsen T, Terplan M, Hood M, Bernson D, Diop H, et al. Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts. Obstet Gynecol. 2018;132:466–74 A comprehensive study comparing fatal and non-fatal opioid events in women receiving and not receiving pharmacotherapy. CrossRef
McLafferty LP, Becker M, Dresner N, Meltzer-Brody S, Gopalan P, Glance J, et al. Guidelines for the management of pregnant women with substance use disorders. Psychosomatics. 2016;57:115–30. CrossRef
Treatment C for SA. Chapter 13. Medication-assisted treatment for opioid addiction during pregnancy. Substance Abuse and Mental Health Services Administration (US). 2005. https://www.ncbi.nlm.nih.gov/books/NBK64148/. Accessed 12 Nov 2018.
New treatment guidance issued for pregnant and parenting mothers with opioid use disorder and their infants | SAMHSA - Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/newsroom/press-announcements/201802070200. Accessed 30 May 2018.
The ASAM National Practice Guideline Supplement.pdf - asam-national-practice-guideline-supplement.pdf. http://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf?sfvrsn=24#search=%22comfort%20medications%20for%20opioid%20withdrawal%22. Accessed 15 Dec 2016.
Lund IO, Fitzsimons H, Tuten M, Chisolm MS, O’Grady KE, Jones HE. Comparing methadone and buprenorphine maintenance with methadone-assisted withdrawal for the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. Subst Abus Rehabil. 2012;3(Suppl 1):17–25.
Jones HE, O’Grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict. 2008;17:372–86. CrossRef
Guan Q, Sproule BA, Vigod SN, Cadarette SM, Greaves S, Martins D, et al. Impact of timing of methadone initiation on perinatal outcomes following delivery among pregnant women on methadone maintenance therapy in Ontario. Addiction. 2019;114(2):268–77. CrossRef
Jones HE, Fischer G, Heil SH, Kaltenbach K, Martin PR, Coyle MG, et al. Maternal opioid treatment: human experimental research (MOTHER)--approach, issues and lessons learned. Addiction. 2012;107(Suppl 1):28–35. CrossRef
Meyer MC, Johnston AM, Crocker AM, Heil SH. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J Addict Med. 2015;9:81–6. CrossRef
Zedler BK, Mann AL, Kim MM, Amick HR, Joyce AR, Murrelle EL, et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction. 2016;111(12):2115–28. CrossRef
Wiegand SL, Stringer EM, Stuebe AM, Jones H, Seashore C, Thorp J. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol. 2015;125(2):363–8. CrossRef
Hulse G, O’Neill G. A possible role for implantable naltrexone in the management of the high-risk pregnant heroin user. Aust N Z J Obstet Gynaecol. 2002;42:104–5. CrossRef
Hulse G, O’Neil G. Using naltrexone implants in the management of the pregnant heroin user. Aust N Z J Obstet Gynaecol. 2002;42:569–73. CrossRef
Saia KA, Schiff D, Wachman EM, Mehta P, Vilkins A, Sia M, et al. Caring for pregnant women with opioid use disorder in the USA: expanding and improving treatment. Curr Obstet Gynecol Rep. 2016;5:257–63. CrossRef
brian.dominguez. New treatment guidance issued for pregnant and parenting mothers with opioid use disorder and their infants. 2018. https://www.samhsa.gov/newsroom/press-announcements/201802070200. Accessed 30 May 2018.
Standardizing care improves outcomes for infants born with neonatal opioid withdrawal syndrome. https://public.vtoxford.org/pediatrics-article-on-improving-care-for-nas/. Accessed 19 Dec 2016.
Mccarthy JJ, Leamon MH, Finnegan LP, Fassbender C. Opioid dependence and pregnancy: minimizing stress on the fetal brain. Am J Obstet Gynecol. 2017;216(3):226–31. CrossRef
Hser Y-I, Kagihara J, Huang D, Evans E, Messina N. Mortality among substance-using mothers in California: a 10-year prospective study: mortality among substance-using mothers. Addiction. 2012;107:215–22. CrossRef
- Caring for Pregnant Women with Opioid Use Disorder
Yeon Woo Lee
- Springer US
Neu im Fachgebiet Gynäkologie und Geburtshilfe
Meistgelesene Bücher aus dem Fachgebiet
Mail Icon II